Double-blind crossover comparison of triazolam and lorazepam in the posthypnotic state.
A double-blind crossover study compared the hypnotic effect, daytime carryover, and safety of triazolam 0.5 mg, lorazepam 2 mg, and placebo. The two active drugs were similar in hypnotic effect and superior to placebo. Patients reported more drowsiness upon awakening and more sleepiness in mid-morning and mid-afternoon after nights on lorazepam than nights on triazolam or placebo. The most common side effects--drowsiness, lightheadedness, restlessness, impaired coordination, dizziness, and nausea--were reported three times as often with lorazepam than with triazolam or placebo.
D000293:Adolescent; D000328:Adult; D017109:Akathisia, Drug-Induced; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004244:Dizziness / Q000139:chemically induced; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010919:Placebos; D011597:Psychomotor Performance; D012890:Sleep / Q000187:drug effects; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D012894:Sleep Stages; D014229:Triazolam / Q000009:adverse effects / Q000627:therapeutic use*
D014151:Anti-Anxiety Agents; D010919:Placebos; D014229:Triazolam; D008140:Lorazepam